Clinical observation of desmopressin in the treatment of 15 patients with DDAVP.
10.3760/cma.j.issn.0253-2727.2019.04.009
- Author:
Meng Jia HOU
1
,
2
,
3
;
Zi Qiang YU
;
Zhen Ni MA
;
Wei ZHANG
;
Xia BAI
;
Li Juan CAO
;
Jian SU
;
Ping Ping SHA
;
Zhao Yue WANG
;
Chang Geng RUAN
Author Information
1. Department of Hematology, First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
2. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health
3. Collaborative Innovation Center of Hematology, Soochow university, Suzhou 215006, China.
- Publication Type:Journal Article
- Keywords:
Desmopressin;
Treatment outcome;
von Willebrand diseases;
von Willebrand factor
- MeSH:
Adolescent;
Adult;
Child;
Deamino Arginine Vasopressin;
Female;
Hemostatics;
Humans;
Male;
Middle Aged;
Young Adult;
von Willebrand Diseases;
von Willebrand Factor
- From:
Chinese Journal of Hematology
2019;40(4):312-316
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the significance of DDAVP use in the diagnosis and treatment of VWD. Methods: An analysis of 15 VWD cases who referred to Hematology Division of First affiliated Hospital of Soochow University and treated with DDAVP from March 2016 to August 2018 was conducted. Efficacy and treatment response of DDAVP were monitored by observations of changes in factor Ⅷ procoagulant (FⅧ∶C) and von Willebrand Factor (VWF) related indicators before and 2 h after DDAVP injection. Results: Of 15 cases with VWD, 7 males and 8 females with a median age of 23 (6-46) years, 7 of 9 type I VWD patients achieved complete response (CR) , 1 type 2A VWD case CR, 5 type 3 VWD ones no response (NR) . The VWF multimer analysis in 5 patients combined with other plasma VWF values were in accordance with the known diagnosis. Conclusions: DDAVP was effective in most type 1 patients, and ineffective in some type 2 and almost all type 3 cases. It was helpful for diagnosis and subsequent treatment planning.
